GC Green Cross, 3rd Additional Production of COVID-19 Plasma Treatment

[Image source=Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] GC Green Cross has completed the third batch production of its COVID-19 plasma treatment drug, ‘GC5131A’.

On the 1st, GC Green Cross announced, "We have completed preparations to supply additional GC5131A to medical sites."

The plasma used in this third additional production batch was 240ℓ, the same amount as in the second production. All produced plasma will be used to treat COVID-19 patients in medical facilities.

The drug under clinical trials can be used for patients in critical condition or those without alternative treatment options. Since the first approval for compassionate use at Chilgok Kyungpook National University Hospital last October, GC5131A has obtained the highest number of approvals (10 cases) among COVID-19 treatments developed domestically.

GC Green Cross stated, "With no proper treatment alternatives for severe COVID-19 patients, the high demand from medical sites has demonstrated the potential of GC5131A as a treatment option for severe cases."

Due to the nature of plasma treatments, production is limited to the amount of plasma secured from recovered COVID-19 patients. However, with recent group plasma donations continuing smoothly, plasma supply is stable, and additional production is expected to accelerate.

Kim Jin, Head of Medical Affairs at GC Green Cross, said, “Inquiries from the medical community regarding the use of the COVID-19 plasma treatment drug in clinical settings continue steadily,” adding, “We will do our best to complete the development of this plasma treatment drug, which was made possible by the collective efforts of the people.”